Atricure Stock Analysis

ATRC Stock  USD 35.68  0.35  0.97%   
AtriCure is undervalued with Real Value of 44.15 and Target Price of 65.33. The main objective of AtriCure stock analysis is to determine its intrinsic value, which is an estimate of what AtriCure is worth, separate from its market price. There are two main types of AtriCure's stock analysis: fundamental analysis and technical analysis.
The AtriCure stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and AtriCure's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.

AtriCure Stock Analysis Notes

About 97.0% of the company shares are held by institutions such as insurance companies. The book value of AtriCure was presently reported as 9.54. The company recorded a loss per share of 0.82. AtriCure last dividend was issued on the 30th of September 2010. AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Atricure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 875 people. For more info on AtriCure please contact Michael Carrel at 513 755 4100 or go to https://www.atricure.com.

AtriCure Quarterly Total Revenue

115.91 Million

AtriCure Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. AtriCure's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding AtriCure or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
AtriCure appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 399.25 M. Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 245.94 M.
Over 97.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

AtriCure Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AtriCure previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

AtriCure Largest EPS Surprises

Earnings surprises can significantly impact AtriCure's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-08-01
2013-06-30-0.1-0.090.0110 
2012-08-02
2012-06-30-0.07-0.08-0.0114 
2011-11-01
2011-09-30-0.08-0.070.0112 
View All Earnings Estimates

AtriCure Environmental, Social, and Governance (ESG) Scores

AtriCure's ESG score is a quantitative measure that evaluates AtriCure's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of AtriCure's operations that may have significant financial implications and affect AtriCure's stock price as well as guide investors towards more socially responsible investments.

AtriCure Stock Institutional Investors

Shares
Geode Capital Management, Llc2024-06-30
1.1 M
Ubs Asset Mgmt Americas Inc2024-09-30
M
Gw&k Investment Management, Llc2024-09-30
M
Fmr Inc2024-09-30
973.5 K
Millennium Management Llc2024-06-30
952.8 K
Fiera Capital Corporation2024-06-30
918.2 K
Neuberger Berman Group Llc2024-06-30
868.4 K
Wasatch Advisors Lp2024-06-30
789.8 K
Morgan Stanley - Brokerage Accounts2024-06-30
782.9 K
Vanguard Group Inc2024-09-30
4.7 M
Blackrock Inc2024-06-30
4.6 M
Note, although AtriCure's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

AtriCure Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.77 B.

AtriCure Profitablity

The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.06.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.10)(0.10)
Return On Capital Employed(0.05)(0.05)
Return On Assets(0.05)(0.05)
Return On Equity(0.07)(0.07)

Management Efficiency

AtriCure has return on total asset (ROA) of (0.0351) % which means that it has lost $0.0351 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0839) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.05. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.
Last ReportedProjected for Next Year
Book Value Per Share 10.07  10.57 
Tangible Book Value Per Share 3.61  3.80 
Enterprise Value Over EBITDA(202.61)(192.48)
Price Book Value Ratio 3.55  3.76 
Enterprise Value Multiple(202.61)(192.48)
Price Fair Value 3.55  3.76 
Enterprise Value73.6 M54.9 M
The strategic initiatives led by AtriCure's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Operating Margin
(0.06)
Profit Margin
(0.09)
Beta
1.408
Return On Assets
(0.04)
Return On Equity
(0.08)

Technical Drivers

As of the 22nd of November, AtriCure shows the Mean Deviation of 1.92, downside deviation of 1.92, and Risk Adjusted Performance of 0.1759. AtriCure technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

AtriCure Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. AtriCure middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for AtriCure. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

AtriCure Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AtriCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

AtriCure Outstanding Bonds

AtriCure issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AtriCure uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AtriCure bonds can be classified according to their maturity, which is the date when AtriCure has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

AtriCure Predictive Daily Indicators

AtriCure intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AtriCure stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

AtriCure Corporate Filings

13A
14th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
12th of November 2024
Other Reports
ViewVerify
10Q
30th of October 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
29th of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
18th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
19th of August 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
16th of August 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10Q
31st of July 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify

AtriCure Forecast Models

AtriCure's time-series forecasting models are one of many AtriCure's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AtriCure's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About AtriCure Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how AtriCure prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AtriCure shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AtriCure. By using and applying AtriCure Stock analysis, traders can create a robust methodology for identifying AtriCure entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.07)(0.08)
Operating Profit Margin(0.07)(0.07)
Net Loss(0.08)(0.08)
Gross Profit Margin 0.75  0.58 

Current AtriCure Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AtriCure analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AtriCure analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
65.33Strong Buy9Odds
AtriCure current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most AtriCure analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand AtriCure stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of AtriCure, talking to its executives and customers, or listening to AtriCure conference calls.
AtriCure Analyst Advice Details

AtriCure Stock Analysis Indicators

AtriCure stock analysis indicators help investors evaluate how AtriCure stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AtriCure shares will generate the highest return on investment. By understating and applying AtriCure stock analysis, traders can identify AtriCure position entry and exit signals to maximize returns.
Begin Period Cash Flow58.1 M
Long Term Debt60.6 M
Common Stock Shares Outstanding46.3 M
Total Stockholder Equity466.2 M
Tax Provision591 K
Property Plant And Equipment Net46.8 M
Cash And Short Term Investments137.3 M
Cash84.3 M
Accounts Payable27.4 M
Net Debt-9.8 M
50 Day M A30.434
Total Current Liabilities74.6 M
Other Operating Expenses425.9 M
Non Current Assets Total347.7 M
Non Currrent Assets Other2.2 M
Stock Based Compensation35.7 M

Complementary Tools for AtriCure Stock analysis

When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges